| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 204.13 | 5.1% | 11.9% |
| Total Income | 204.13 | 5.1% | 11.9% |
| Expenditure | 190.15 | 6.6% | 12.9% |
| PBT | 14.15 | 699.4% | 22.3% |
| Net Profit | 5.01 | 39.9% | 66.3% |
| OPM | 6.85% | 1.36pp | 0.77pp |
| NPM | 2.45% | 1.84pp | 5.70pp |
| EPS | 0.09 | 40.0% | 65.4% |
Repligen Announces Acquisition of BioLife Solutions and Preliminary Q2 2026 Results
22 Jul 2026 · 22 Jul, 6:32 pm
Summary
Repligen Corporation announced its definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion, a strategic move aimed at expanding its cell therapy capabilities. The transaction, valued at $31.00 per share for BioLife stockholders, is expected to enhance Repligen's top-line growth, adjusted margins, and adjusted earnings per share, with projected accretion of at least 5 cents in year one and 25 cents in year two. Concurrently, Repligen reported preliminary second quarter 2026 revenue growth of approximately 12% (13% organic), while BioLife Solutions posted preliminary Q2 2026 revenue of $28.5 million, up 21% year-over-year. The acquisition is slated for completion in the fourth quarter of 2026, pending regulatory and stockholder approvals.
Key Highlights
- 1
Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a total enterprise value of approximately $1.5 billion.
- 2
BioLife stockholders are set to receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, valuing the transaction at $31.00 per share.
- 3
The acquisition is projected to be accretive to Repligen’s top-line growth, adjusted margins, and adjusted earnings per share by at least 5 cents in year one and at least 25 cents in year two.
- 4
Repligen reported preliminary second quarter 2026 revenue growth of approximately 12% as reported and 13% on an organic basis year-over-year.
- 5
BioLife Solutions reported preliminary second quarter 2026 revenue of $28.5 million, representing a 21% increase compared to $23.4 million in the second quarter of 2025.
- 6
The transaction is expected to generate at least $20 million in synergies in year one and at least $30 million in year two through cost efficiencies and optimization.
- 7
The acquisition is targeted to close in the fourth quarter of 2026, pending customary regulatory approvals and BioLife stockholder approval.
Management Comments
Olivier Loeillot
The acquisition of BioLife represents a natural next step in the evolution of our strategy and further strengthens our position as a leading provider of mission-critical technologies for biologics manufacturing. BioLife brings a highly differentiated portfolio of products including a market-leading biopreservation media platform and other cell processing tools. This opportunity will expand Repligen’s presence in the rapidly growing cell therapy market, broaden our solutions offering to cell therapy customers, and add a deeply embedded, high-margin consumables business with attractive recurring revenue. Just as important, we believe our shared culture of innovation and customer centricity will create a strong foundation for future growth and value creation. This morning, we announced that we have entered into a definitive agreement to acquire BioLife Solutions, a highly differentiated leader in cell processing tools for cell therapy. You can find the press release on our investor relations website here. In addition, we will host a call at 8:30am ET this morning, the webcast will be accessible via the Investor Relations section of the Company’s website. First, a little about BioLife: the company is a market leader in cell processing tools including biopreservation media for cell therapy. Their differentiated product portfolio, led by CryoStor®, supports a number of commercially approved cell therapies and many clinical trials. BioLife is based in Bothell, WA and has approximately 160 employees. This acquisition is a natural next step in the evolution of our strategy and further strengthens our position as a leading provider of bioprocessing technologies by fast-tracking our leadership in cell therapy and broadens our offering for this attractive end-market. BioLife is highly complementary to our portfolio and shares our culture of innovation and our commitment to advancing the science that improves human health worldwide. Separately, alongside today’s news we also shared preliminary highlights from our second quarter results, which reflect continued strong performance. This momentum in our business during such an exciting time at our company is a testament to your hard work.
Roderick de Greef
Over the past several years, we have successfully repositioned BioLife around our market-leading biopreservation media franchise, while strengthening our financial profile and establishing a durable foundation for profitable growth. Repligen shares our commitment to providing innovative, differentiated, and enabling tools that help customers bring important therapies to patients. Its global commercial reach, complementary technologies and proven operating capabilities make Repligen an ideal partner for BioLife. This Transaction will expand the reach and impact of our portfolio, while providing BioLife stockholders with immediate cash value and the opportunity to participate in Repligen’s future growth.
Informational and educational content only. Not investment advice.